Cargando…

Efficacy of telbivudine in Taiwanese chronic hepatitis B patients compared with GLOBE extension study and predicting treatment outcome by HBV DNA kinetics at Week 24

BACKGROUND: The aims of this study were to compare results from a Taiwanese sub-study of the GLOBE 2303 telbivudine study and evaluate the HBV DNA kinetics. METHODS: Forty-one Taiwanese patients were treated for an additional 2 years with telbivudine. Efficacy endpoints were the same as the GLOBE st...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hsu, Chao Wei, Chao, You Chen, Lee, Chuan Mo, Chang, Ting Tsung, Chen, Yi Cheng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3563525/ https://www.ncbi.nlm.nih.gov/pubmed/23234302 http://dx.doi.org/10.1186/1471-230X-12-178

Ejemplares similares

52-Week Efficacy and Safety of Telbivudine with Conditional Tenofovir Intensification at Week 24 in HBeAg-Positive Chronic Hepatitis B
por: Piratvisuth, Teerha, et al.
Publicado: (2013)

Effectiveness of tenofovir or telbivudine in preventing HBV vertical transmission for pregnancy
por: Zeng, Jianyong, et al.
Publicado: (2019)

Efficacy and safety of telbivudine treatment for the prevention of HBV perinatal transmission
por: Ren, Cuicui, et al.
Publicado: (2020)

Telbivudine and adefovir combination therapy for patients with chronic lamivudine-resistant hepatitis B virus infections
por: Lin, Ming-Tsung, et al.
Publicado: (2013)

Antiviral kinetics of tenofovir alafenamide and tenofovir disoproxil fumarate over 24 weeks in women of childbearing potential with chronic HBV
por: Pan, Calvin Q., et al.
Publicado: (2021)

Telbivudine treatment started in early and middle pregnancy completely blocks HBV vertical transmission
por: Sun, Weihui, et al.
Publicado: (2017)

Durability of Telbivudine-Associated Improvement of Renal Function Following Withdrawal or Switching of Antivirals in Chronic Hepatitis B Patients
por: Hsu, Chao-Wei, et al.
Publicado: (2017)

Kinetics of hepatitis B surface antigen and estimated glomerular filtration rate in telbivudine-treated hepatitis B patients with different rescue strategies
por: Yu, Hsien-Chung, et al.
Publicado: (2020)

Telbivudine can safely reduce mother-to-child transmission in chronic hepatitis B women after 12 weeks of gestation
por: Han, Li-fen, et al.
Publicado: (2019)

Safety and efficacy of telbivudine for the treatment of chronic hepatitis B
por: Osborn, Melissa K
Publicado: (2009)

Effect and Predictive Elements for 52 Weeks’ Telbivudine Treatment on Naïve HBeAg positive Chronic Hepatitis B
por: Zhu, Xiao-Feng, et al.
Publicado: (2011)

Efficacy of 104-week Telbivudine-based optimization strategy in patients with HBeAg-negative chronic hepatitis B virus infections
por: Gan, Weiqiang, et al.
Publicado: (2020)

Renal Function Improvement by Telbivudine in Liver Transplant Recipients with Chronic Kidney Disease
por: Lee, Wei-Chen, et al.
Publicado: (2017)

Effectiveness of telbivudine antiviral treatment in patients with hepatitis B virus-associated glomerulonephritis: A 104-week pilot study
por: Yan, Zhaoping, et al.
Publicado: (2018)

Early Viral Kinetics with Telbivudine, Tenofovir or Combination of Both in Immunotolerant Patients with Hepatitis B e Antigen-Positive Chronic Hepatitis B
por: Leung, Nancy W. Y., et al.
Publicado: (2014)

Infant immune response to hepatitis B vaccine after fetal exposure to telbivudine
por: Li, Yandi, et al.
Publicado: (2022)

Telbivudine-Induced Myopathy: Clinical Features, Histopathological Characteristics, and Risk Factors
por: Lan, Min-Yu, et al.
Publicado: (2023)

Two cases of telbivudine-induced myopathy in siblings with chronic hepatitis B
por: Kim, Eun Hye, et al.
Publicado: (2013)

Effectiveness of entecavir or telbivudine therapy in patients with chronic hepatitis B virus infection pre-treated with interferon compared with de novo therapy with entecavir and telbivudine
por: Cai, Shaohang, et al.
Publicado: (2017)

Comparison of the Efficacies and Safety of Combined Therapy between Telbivudine Plus Adefovir and Lamivudine Plus Adefovir in Patients with Hepatitis B Virus Infection in Real-World Practice
por: Lin, Ming-Tsung, et al.
Publicado: (2016)

Comparison of the efficacy of lamivudine and telbivudine in the treatment of chronic hepatitis B: a systematic review
por: Zhao, Shushan, et al.
Publicado: (2010)

Telbivudine treatment of hepatitis B virus-infected pregnant women at different gestational stages for the prevention of mother-to-child transmission: Outcomes of telbivudine treatment during pregnancy
por: Tan, Zhangmin, et al.
Publicado: (2016)

Telbivudine on IgG-associated hypergammaglobulinemia and TGF-β1 hyperactivity in hepatitis B virus-related liver cirrhosis
por: Ho, Cheng-Hsun, et al.
Publicado: (2019)

Comparing Efficacy of Lamivudine, Adefovir Dipivoxil, Telbivudine, and Entecavir in Treating Nucleoside Analogues Naïve for HBeAg-Negative Hepatitis B with Medium Hepatitis B Virus (HBV) DNA Levels
por: Shi, Hong, et al.
Publicado: (2017)

Clinicopathological Features of Telbivudine-Associated Myopathy
por: Ambang, Tomica, et al.
Publicado: (2016)

Comparison of the efficacy and safety of tenofovir and telbivudine in interrupting mother-to-child transmission of hepatitis B virus
por: Zhu, Bo, et al.
Publicado: (2021)

Factors Related to Significant Improvement of Estimated Glomerular Filtration Rates in Chronic Hepatitis B Patients Receiving Telbivudine Therapy
por: Lin, Te-Fu, et al.
Publicado: (2017)

Effects of Telbivudine Treatment on the Circulating CD4(+) T-Cell Subpopulations in Chronic Hepatitis B Patients
por: Zheng, Yanhua, et al.
Publicado: (2012)

Decrease of Serum Angiotensin Converting Enzyme Levels Upon Telbivudine Treatment for Chronic Hepatitis B Virus Infection and Negative Correlations Between the Enzyme Levels and Estimated Glumerular Filtration Rates
por: Liang, Kung-Hao, et al.
Publicado: (2014)

Pegylated interferon/telbivudine sequential therapy in Hepatitis Be antigen negative severe chronic hepatitis B patient
por: Caroleo, Benedetto, et al.
Publicado: (2013)

Composition and Interactions of Hepatitis B Virus Quasispecies Defined the Virological Response During Telbivudine Therapy
por: Zhou, Bin, et al.
Publicado: (2015)

Efficacy and safety of continuous 4-year telbivudine treatment in patients with chronic hepatitis B
por: Wang, Y, et al.
Publicado: (2013)

Efficacy of telbivudine on interruption of hepatitis B virus vertical transmission: a meta-analysis
por: Liu, Min-Hui, et al.
Publicado: (2013)

Role of tenofovir and telbivudine in treatment of hepatitis B related acute on chronic liver failure
por: Malakar, Debraj, et al.
Publicado: (2021)

Myotoxicity of telbivudine in pre-existing muscle damage
por: Finsterer, Josef, et al.
Publicado: (2010)

Comparison of telbivudine and entecavir on the change of off- treatment eGFR after 3 years of treatment in non-cirrhotic chronic hepatitis B patients
por: Lin, Yang-Sheng, et al.
Publicado: (2017)

Concordance of SVR12, SVR24 and SVR durability in Taiwanese chronic hepatitis C patients with direct-acting antivirals
por: Lin, Chuan-Pin, et al.
Publicado: (2021)

Long-Term Telbivudine Treatment Results in Resolution of Liver Inflammation and Fibrosis in Patients with Chronic Hepatitis B
por: Hou, Jin-Lin, et al.
Publicado: (2015)

Telbivudine versus entecavir in patients with undetectable hepatitis B virus DNA: a randomized trial
por: An, Jihyun, et al.
Publicado: (2017)

Case report: lactic acidosis and rhabdomyolysis during telbivudine and tenofovir treatment for chronic hepatitis B
por: Ying, Yue, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_m9po7msg6mpm9aqdusoncqr81i